PMID- 27743397
OWN - NLM
STAT- MEDLINE
DCOM- 20180314
LR  - 20180314
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 44
IP  - 2
DP  - 2017 Feb
TI  - Adalimumab administration after infliximab therapy is a successful treatment
      strategy for generalized pustular psoriasis.
PG  - 202-204
LID - 10.1111/1346-8138.13632 [doi]
AB  - We report a case of a 70-year-old woman with generalized pustular psoriasis (GPP)
      who responded well to infliximab therapy and adalimumab therapy after secondary
      failure of infliximab therapy, but did not respond to ustekinumab therapy. We
      speculate that the pathogenic factor in this case favored anti-tumor necrosis
      factor (TNF)-alpha therapy to anti-interleukin-12/23 therapy. Herein, we also
      briefly present three additional cases of treatment with adalimumab after
      secondary failure of infliximab. GPP is often difficult to treat, and no
      placebo-controlled trials have been conducted to guide the use of biologics
      against it because of a paucity of cases. Infliximab and adalimumab are
      anti-TNF-alpha antibodies that specifically block the interaction of TNF-alpha
      with its receptors. Infliximab has been reported to be effective, with a rapid
      clearance of symptoms, even in cases of severe GPP. Adalimumab could be a good
      biologic candidate that can be administrated after secondary failure of
      infliximab therapy.
CI  - (c) 2016 Japanese Dermatological Association.
FAU - Matsumoto, Ai
AU  - Matsumoto A
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
FAU - Komine, Mayumi
AU  - Komine M
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
FAU - Karakawa, Masaru
AU  - Karakawa M
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
FAU - Kishimoto, Megumi
AU  - Kishimoto M
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
FAU - Ohtsuki, Mamitaro
AU  - Ohtsuki M
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20161015
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dermatologic Agents)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*administration & dosage
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Dermatologic Agents/*administration & dosage
MH  - Female
MH  - Humans
MH  - Infliximab/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
OTO - NOTNLM
OT  - adalimumab
OT  - anti-tumor necrosis factor antibody
OT  - generalized pustular psoriasis
OT  - treatment
OT  - ustekinumab
EDAT- 2016/10/16 06:00
MHDA- 2018/03/15 06:00
CRDT- 2016/10/16 06:00
PHST- 2016/02/11 00:00 [received]
PHST- 2016/08/24 00:00 [accepted]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2018/03/15 06:00 [medline]
PHST- 2016/10/16 06:00 [entrez]
AID - 10.1111/1346-8138.13632 [doi]
PST - ppublish
SO  - J Dermatol. 2017 Feb;44(2):202-204. doi: 10.1111/1346-8138.13632. Epub 2016 Oct
      15.